LEAD CLINICAL PROGRAM
Zindol®: development and evidence
A botanical drug candidate for chemotherapy-induced nausea and vomiting
PROGRAM STATUS
Phase 3-ready
Zindol® is being prepared for pivotal development.
PUBLISHED GINGER STUDY
744
patients randomized; 576 included in the final analysis.
REPORTED OUTCOME
p=0.003
Lower acute nausea severity on day one of chemotherapy.
The published study evaluated Zindol® DS, a precursor ginger product sold as a Dietary Supplement by Aphios; its results are supporting research, but does not represent Zindol® product clinical trial results.
APHIOS / THERAPEUTIC PROGRAMS
Pipeline at a glance
Selected programs beyond lead asset Zindol®
APH-1501
Aphios Pharma LLC
Opioid use disorder relapse prevention
Extended-release cannabidiol and low-dose naltrexone
STATUS
Preclinical development and planning for IND-enabling studies and Phase 2 studies
APH-1505
Aphios Pharma LLC
Chronic epilepsy
Extended-release cannabidiol
STATUS
Preclinical development and planning for IND-enabling studies and Phase 2 studies
APH-1105
Amylon LLC
Alzheimer’s disease
Nanoencapsulated Bryostatin-1
STATUS
Preclinical development and planning for IND-enabling studies and Phase 2 studies
APH-1104
Amylon LLC
Alzheimer’s disease
Nanoencapsulated Bryostatin-22
STATUS
Preclinical development and planning for IND-enabling studies and Phase 1 studies
APH-2502
Amylon LLC
Neuroinflammation
CCR5 antagonist program
STATUS
Indication-specific development planning
Bryolat™
Bryolat LLC
HIV-1 latency
Nanoparticle delivery research
STATUS
Research and preclinical development
APHIOS / ENABLING TECHNOLOGIES
Technologies behind the pipeline
From natural compounds to differentiated therapeutics
Aphios develops proprietary technologies for discovery, purification, manufacturing, and delivery. These platforms support our therapeutic pipeline and opportunities for feasibility studies, co-development, and licensing.
Fractionate and Discover
CXF™
Supercritical-fluid technology extracts and fractionates bioactive compounds from natural sources, helping identify partially purified candidates for further development.
Purify and Manufacture
CXP™
Our purification technology separates and concentrates selected compounds, supporting the production of materials for formulation, research, and drug development.
Formulate and Deliver
SFS-PNP™ · SFS-PNS™ · SFS-CFN™
Protein, polymer, and phospholipid nanotechnologies support drug formulation and delivery. Applications include extended-release cannabinoid formulations in Aphios Pharma and nanoencapsulated Bryostatin programs in Amylon.
Advance Pathogen Safety
CFI®
A complementary platform addresses pathogen reduction in biologics and plasma products without heat, chemicals or irradiation, creating opportunities for collaboration in product safety and manufacturing.
APHIOS / BUSINESS MODEL & PARTNERING
Business Model and Partnering
Partnering for the Future of Human Health®
Aphios combines proprietary therapeutic development with licensing and collaboration around its enabling technologies. Development responsibilities, financing, and partnership terms are tailored to each opportunity.
Develop Proprietary Therapeutics
We advance selected drug candidates toward clinical development, with Zindol® as our lead program and additional programs addressing addiction, neurological disorders, and HIV-1 latency.
Focus Development Through Program Entities
Zindol® LLC, Aphios Pharma LLC, Amylon LLC, and Bryolat LLC provide a focus for individual programs. Ownership, rights, and financing arrangements depend on the entity and proposed transaction.
License Products and Technologies
We seek licensing relationships suited to a partner’s therapeutic interests, technical needs, and geographic markets. Available rights and responsibilities are defined for each agreement.
Collaborate From Feasibility to Development
Collaborations may begin with a feasibility study using a partner’s compound or product and progress to joint research, co-development, or licensing as agreed milestones are achieved.
APHIOS / COMPANY PROGRESS & LEADERSHIP
Company Progress and Leadership
Scientific innovation. Focused development. Experienced leadership.
Aphios brings together proprietary technologies, federally supported research, and a multidisciplinary team to advance its therapeutic pipeline.
85+ Issued Patents
An intellectual property portfolio spanning drug discovery, manufacturing, delivery, and pathogen-safety technologies and therapeutics.
More Than $20 Million in NIH Grant Funding
Federal research support has helped advance Aphios’s technologies and therapeutic programs.
Advancing Our Programs
Zindol® is our lead, Phase 3-ready program. Additional programs address opioid use disorder relapse prevention, chronic epilepsy, Alzheimer’s disease, neuroinflammation, and HIV-1 latency.
Experienced Leadership
Founder, President & CEO Dr. Trevor P. Castor leads a team with expertise in scientific research, clinical development, finance, and commercialization, supported by scientific advisors and the Board of Directors.
APHIOS PHARMA LLC ON NETCAPITAL
Crowdfunding Campaign Preparing to go Live
Aphios Pharma LLC, a subsidiary of Aphios Corporation, is developing therapeutics using proprietary drug delivery technologies. Its crowdfunding offering will be soon available on Netcapital.
Visit the offering page for information about Aphios Pharma, the offering terms, and investment risks.
Join Our Mailing List
Stay up to date with Aphios by subscribing to our mailing list! Get the latest news on innovative therapies and advancements in pharmaceutical development.